Healthcare [ 5/11 ] | Biotechnology [ 54/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 23 | -0.72 Decreased by -820.00% | -0.69 Decreased by -6.30% |
| Mar 15, 23 | -0.72 Decreased by -53.19% | -0.28 Decreased by -561.22% |
| Nov 8, 22 | -0.53 Decreased by -20.45% | -0.53 |
| Aug 10, 22 | -0.56 Decreased by -64.71% | -0.45 Decreased by -54.32% |
| May 12, 22 | 0.10 Increased by +112.20% | -0.18 Increased by +864.20% |
| Mar 15, 22 | -0.47 Decreased by -2.17% | -0.42 Decreased by -28.34% |
| Nov 10, 21 | -0.44 Increased by +84.51% | -0.44 |
| Aug 12, 21 | -0.34 Increased by +67.62% | -0.53 Increased by +67.64% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by -100.00% | -29.63 M Decreased by -741.55% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | -24.99 M Decreased by -515.12% | -28.10 M Decreased by -77.72% | Increased by +112.46% Increased by +142.81% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -21.01 M Decreased by -49.91% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | -22.37 M Decreased by -106.09% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 24.99 M Increased by +727.73% | 4.62 M Increased by +121.66% | Increased by +18.48% Decreased by -96.55% |
| Dec 31, 21 | 6.02 M Increased by +11.28% | -15.81 M Decreased by -76.52% | Decreased by -262.67% Decreased by -58.64% |
| Sep 30, 21 | 3.43 M Increased by +13.24% | -14.01 M Increased by +5.18% | Decreased by -408.66% Increased by +16.27% |
| Jun 30, 21 | 4.81 M Decreased by -35.51% | -10.85 M Decreased by -28.37% | Decreased by -225.47% Decreased by -99.07% |
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.